PLATFORM

SAMiRNA

Intellectual Property

siRNAgen Therapeutics maintains a comprehensive intellectual property (IP) portfolio that solidifies our position as a leader in RNAi therapeutics. Our patents cover the core components of the SAMiRNA platform, including the design of amphiphilic molecules, siRNA conjugation methods, and therapeutic applications across multiple disease indications.

Our IP strategy encompasses:

  • Composition Patents: Protecting the unique amphiphilic molecules and micelle structures that form the SAMiRNA platform.
  • Delivery Method Patents: Covering proprietary techniques for targeted siRNA delivery and nanoparticle functionalization.
  • Therapeutic Application Patents: Securing the use of SAMiRNA for specific diseases, including fibrosis and cancer.
  • Manufacturing Process Patents: Safeguarding scalable production methods for SAMiRNA nanoparticles, ensuring commercial viability.

This extensive IP portfolio enables siRNAgen to pursue strategic partnerships, license our technology, and protect our innovations in the competitive RNAi therapeutics landscape. Ongoing patent filings expand the scope of SAMiRNA applications, supporting our mission to address unmet medical needs globally.

Intellectual Property